Friday, February 27, 2009

Link: LineRate Systems Brings Disruptive Innovation to Network Appliances

Local tech entrepreneurship blog RockyRadar recently featured LineRate Systems, a company spun out of CU-Boulder's Core Research Lab. LineRate is seeking to replace expensive and highly specialized “black box” network appliances with software solutions tied to off-the-shelf equipment. (Link.)

Monday, February 23, 2009

Podcast: Dr. Richard Noble, CU-Boulder Inventor of the Year

"The Tech Transfer Office here has done some very unique and smart things to help. They’ve started a seed grant program. If they identify a technology they feel needs a little additional work, they provide some seed grants. Our electro-chemical pump received one of these seed grants and got the additional data that allowed us to license it," said Richard Noble, Professor of Chemical & Biological Engineering and CU-Boulder Inventor of the Year for 2008. Dr. Noble discusses his research and work with TTO in this interview.

Listen to the podcast.

Tuesday, February 17, 2009

February 2009 Newsletter Now Available

Highlights from TTO's February 2009 Newsletter:

BioAMPS International to Commercialize CU Antimicrobial Technology
BioAMPS International, LLC and the University of Colorado today announced that BioAMPS has secured an exclusive license for a family of antimicrobial peptides created by two University of Colorado Denver researchers in collaboration with researchers at the University of British Columbia. The Colorado-based company will use these peptides to develop improved treatments for common, potentially lethal drug-resistant bacterial infections.

Septodont Commercializing CU Nanogel Materials for Dental Applications
TTO recently executed an option agreement with Septodont - Confi-Dental Division for novel nanogel materials developed by Jeffrey Stansbury, professor of craniofacial biology at UC Denver. Confi-Dental plans to utilize these novel materials for new dental composite restorative materials, dental cement materials and dental impression materials. Established in 1976 and located in Louisville, CO, Septodont is the world-leading producer of injectable dental anesthetic; Confi-Dental ,a division of Septodont, manufactures a wide range of dental products such as composites, cement and whitening gels. Confi-Dental is also developing products based upon two other novel materials developed at the University of Colorado, both with the advantages of lower shrinkage and lower shrinkage stress compared to other dental materials used today. One of these technologies, developed by Jeffrey Stansbury, is the basis of a product now available on the market called N'Durance. The other technology, invented by Christopher Bowman, professor of chemical and biological engineering at CU-Boulder, is entering clinical trials with a product launch expected during 2010.

National Data Places CU Technology Transfer among Top Performers
The Association of University Technology Managers (AUTM) recently released data (PDF) for 161 US universities for the 2007 fiscal year. The University of Colorado research investigators and Technology Transfer Office (TTO) continue to perform among the top 10% of all universities. CU is tied for seventh place for the number of start-up companies created, 12th place for 2005- 2007 inventions reported to TTO, and 13th place for 2005 - 2007 cumulative income. "These data are gratifying and support CU claims about the high levels of faculty inventive performance and Tech Transfer Office productivity," commented David Allen, CU's Associate Vice President for Technology Transfer. "With licensing staff size is tied for 13th and 2005-2007 cumulative research expenditures tied for 15th, it's clear that tech transfer's resource efficiency is similar to that of the university at large." More recent and comprehensive CU technology transfer performance metrics can be found on the TTO website (PPT).

CU-Boulder Investigators: Pre-proposal Deadline Extended for Renewable Energy Proof of Concept Grants
The TTO and the Energy Initiative at CU-Boulder will soon announce the spring 2009 solicitation for Proof of Concept proposals of up to $50,000 in all areas related to the development of renewable and sustainable energy sources as well as efficient utilization of energy. In order to be eligible, CU-Boulder investigators must complete an invention submission and a one-page pre-proposal by Friday, March 13, 2009 and attend at least one meeting with representatives from the TTO, EI and the Boulder Innovation Center prior to submitting a full proposal in April. The one-page pre-proposal should be a preliminary description of the research project and an explanation of how the project would enhance the commercial potential of the invention. More information is available at https://www.cu.edu/techtransfer/proof/pocg_renew_en.html

Legislative Update: Clean Tech Research Grant Program
Senator Heath and Representative Riesberg have introduced Senate Bill 09-031 (PDF) in support of cleantech-related research and development, and largely modeled after HB 08-1001, the biosciences development bill. If enacted, one quarter of the funds would be directed to university cleantech proof of concept funding up to $50,000 per project matched by university funds, one quarter for matching grants to Colorado cleantech companies up to $150,000 matched by company funds, and half the funds directed to university/industry infrastructure to expand the Colorado Renewable Energy Collaboratory. The bill passed out of Select Committee Joint Select Committee on Job Creation and Economic Growth and the Senate Committee on Local Government and Energy.

Read the full newsletter.

BioAMPS International to Commercialize CU Antimicrobial Technology

CU technology to treat antibiotic-resistant infections exclusively licensed to emerging Colorado pharmaceutical company. (LINK)

DENVER (Feb. 17, 2009). BioAMPS International, LLC and the University of Colorado today announced that BioAMPS has secured an exclusive license for a family of antimicrobial peptides created by two University of Colorado Denver researchers in collaboration with researchers at the University of British Columbia. These peptides will be used to develop improved treatments for common, potentially lethal drug-resistant bacterial infections.

Antimicrobial Peptides (AMPs) are powerful, broad-spectrum antibiotics that have been shown to kill bacteria resistant to conventional antibiotics without inducing further drug resistance. The compounds developed at CU have been engineered to eliminate some known toxicities of previously developed antimicrobial peptides, and have also been recently shown to be effective against tuberculosis and fungi species (Chemical Biology & Drug Design, December 2008). BioAMPS International, based at Aurora’s Science + Technology Park at Fitzsimons, intends to develop antimicrobial peptides to treat drug-resistant gram-positive and gram-negative bacteria associated with both community-acquired and hospital-acquired infections. “We are pleased to secure commercialization rights to this unique, potential solution to the global problem of antibiotic resistance,” said David A. DeLong, BioAMPS’ chief executive officer.

The company will also receive a $100,000 Proof of Concept Investment (POCi) from the CU Technology Transfer Office. CU’s POCi investments are designed to help move promising CU technology closer to becoming commercial products. “We are hopeful about the potential of this technology to provide an important alternative to existing antibiotic drugs, and the POCi funding is a vote of confidence in that regard,” commented Tom Smerdon, Director of Licensing and New Business Development in the CU Technology Transfer Office. “The CU proof of concept investment provides critical development funding and further validates our business model and technology,” added DeLong.

About BioAMPS International
BioAMPs International, LLC is a Colorado-based biotechnology company that discovers and develops proprietary, structurally-guided antimicrobial peptides (AMPs) for the treatment of systemic bacteria infections resistant to conventional antibiotic therapy. Our de novo AMPs are designed to target bacterial cell membranes through a unique mechanism of action while sparing human blood and tissue cells and circumventing the known routes of drug resistance experienced by traditional antibiotics. www.bioamps.com.

Friday, February 13, 2009

Press Release: Septodont Commercializing CU Nanogel Materials for Dental Applications

TTO recently executed an option agreement with Septodont - Confi-Dental Division for novel nanogel materials developed by Jeffrey Stansbury, professor of craniofacial biology at UC Denver. Confi-Dental plans to utilize these novel materials for new dental composite restorative materials, dental cement materials and dental impression materials. Established in 1976 and located in Louisville, CO, Septodont is the world-leading producer of injectable dental anesthetic; Confi-Dental ,a division of Septodont, manufactures a wide range of dental products such as composites, cement and whitening gels.

Confi-Dental is also developing products based upon two other novel materials developed at the University of Colorado, both with the advantages of lower shrinkage and lower shrinkage stress compared to other dental materials used today. One of these, developed by Jeffrey Stansbury, is the basis of a product now available on the market called N’Durance. The other, invented by Christopher Bowman, professor of chemical and biological engineering at CU-Boulder, is entering clinical trials with a product launch expected during 2010.

Wednesday, February 11, 2009

Press Release: National Data Places CU Technology Transfer among Top Performers

CU faculty and tech transfer excel in research, creation of new companies, and cumulative licensing revenue. (LINK)

DenvER (Feb. 11, 2009) The Association of University Technology Managers (AUTM) recently released data (PDF) for 161 US universities for the 2007 fiscal year. The University of Colorado research investigators and Technology Transfer Office (TTO) continue to perform among the top 10% of all universities. CU is tied for 7th place for the number of start-up companies created, 12th place for 2005- 2007 inventions reported to TTO, and 13th place for 2005 – 2007 cumulative income. “These data are gratifying and support CU claims about the high levels of faculty inventive performance and Tech Transfer Office productivity,” commented David Allen, CU’s Associate Vice President for Technology Transfer. “With licensing staff size tied for 13th and 2005-2007 cumulative research expenditures tied for 15th, it’s clear that tech transfer’s resource efficiency is high, and similar to the high resource efficiency of the university at large.” More recent and comprehensive CU technology transfer performance metrics can be found on the TTO website (PPT) and in the 2007-08 Annual Report (PDF).

About the Technology Transfer Office
The CU Technology Transfer Office pursues, protects, packages, and licenses to business the intellectual property generated from research at CU. The TTO provides assistance to faculty, staff, and students, as well as to businesses looking to license or invest in CU technology. For more information about technology transfer at CU, visit www.cu.edu/techtransfer.

About the University of Colorado

The University of Colorado is a three-campus system with four locations: the University of Colorado at Boulder, the University of Colorado at Colorado Springs and the University of Colorado Denver’s downtown Denver campus and Anschutz Medical Campus in Aurora. Nearly 54,000 undergraduate and graduate students are pursuing academic opportunities on CU campuses. CU is a premier teaching and research university, and is ranked sixth among public institutions in federal research expenditures by the National Science Foundation. Academic prestige is marked by the university’s four Nobel laureates, seven MacArthur “genius” Fellows, 18 alumni astronauts and 19 Rhodes Scholars. For more information about all of the CU campuses, go to www.cu.edu.

Link: Colorado 11th in the Nation for Bioscience VC Investment

The Colorado BioScience Association (CBSA) reports:
Colorado ranked 11th among US states for bioscience venture capital investment, with $1.3 billion invested between 2002 and the second quarter of 2008, according to the Colorado Bioscience Roadmap 2008 (PDF), a report produced by Battelle Technology Partnership Practice, and released by the Colorado BioScience Association and Colorado's Office of Economic Development.
(Link to further coverage.)